Results 51 to 60 of about 41,151 (199)
Parkinson’s disease is managed using levodopa; however, as Parkinson’s disease progresses, patients require increased doses of levodopa, which can cause undesirable side effects. Additionally, the oral bioavailability of levodopa decreases in Parkinson’s
Gang Cheng +4 more
doaj +1 more source
Alpha Methyldopahydrazine as an Adjunct to Levodopa Therapy in Parkinson’s Disease [PDF]
D. W. Paty +3 more
openalex +1 more source
Interaction between Levodopa and Methyldopa [PDF]
F B Gibberd, Eric M. Small
openalex +1 more source
Incidence of Side Effects from Levodopa during the Introduction of Treatment [PDF]
R B Godwin-Austen +2 more
openalex +1 more source
The current study presents the creation of a straightforward and sensitive sensor based on ZnO/Co3O4 nanocomposite modified screen-printed electrode (ZnO/Co3O4NC/SPE) for levodopa determination. At ZnO/Co3O4NC/SPE, an oxidative peak for levodopa solution
Tan Wang +10 more
doaj +1 more source
Action of Thymoxamine on Mydriasis induced by Levodopa and Dopamine [PDF]
A. S. D. Spiers +3 more
openalex +1 more source
Dopaminergic medication and deep brain stimulation (DBS) improve motor symptoms in Parkinson's disease (PD), but levodopa response alone may not predict DBS outcomes.
Lukas L. Goede +3 more
doaj +1 more source
Letter: Levodopa in coma due to fulminant hepatitis. [PDF]
P A Contoyiannis +3 more
openalex +1 more source
Levodopa versus levodopa sparing in early parkinson’s disease: can we meet halfway?
Monotherapy is the recommended initial treatment for early Parkinson’s disease. The pharmacological options for initial treatment include dopaminergic agonists, monoamine oxidase B inhibitors, and levodopa formulations.
Mayela Rodríguez-Violante +7 more
doaj +1 more source

